Zymeworks (NASDAQ:ZYME) Price Target Raised to $36.00

Zymeworks (NASDAQ:ZYME) had its target price increased by Truist Financial from $35.00 to $36.00 in a report released on Tuesday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

ZYME has been the topic of a number of other research reports. Jefferies Financial Group reissued a “buy” rating and set a $52.00 price objective on shares of Zymeworks in a report on Friday, October 23rd. B. Riley Financial reissued a “buy” rating and set a $44.00 price target (up from $40.00) on shares of Zymeworks in a report on Monday, August 10th. HC Wainwright lifted their target price on shares of Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research note on Thursday, October 15th. Finally, Deutsche Bank set a $32.00 price objective on shares of Zymeworks in a report on Wednesday, August 26th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.67.

Zymeworks Stock Performance

Shares of NASDAQ ZYME opened at $26.47 on Tuesday. The company’s fifty day moving average price is $27.39 and its 200 day moving average price is $25.46. Zymeworks has a 1 year low of $18.20 and a 1 year high of $31.97. The company has a market capitalization of $1.83 billion, a PE ratio of 50.90 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME) last posted its earnings results on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.01. The company had revenue of $512.92 million for the quarter, compared to analyst estimates of $227.40 million. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. Zymeworks’s revenue was up 828.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS. On average, equities analysts expect that Zymeworks will post 1.31 EPS for the current year.

Insider Buying and Selling at Zymeworks

In other news, EVP Adam Schayowitz sold 13,832 shares of the firm’s stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the completion of the sale, the executive vice president owned 23,205 shares of the company’s stock, valued at $599,849.25. This trade represents a 37.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 37.73% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZYME. Rubric Capital Management LP raised its stake in shares of Zymeworks by 21.7% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after purchasing an additional 1,250,000 shares during the period. BlackRock Inc. bought a new stake in shares of Zymeworks during the second quarter valued at approximately $111,122,000. Perceptive Advisors LLC raised its position in shares of Zymeworks by 7.6% in the 1st quarter. Perceptive Advisors LLC now owns 3,510,078 shares of the company’s stock worth $87,892,000 after purchasing an additional 248,228 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Zymeworks by 20.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,508,069 shares of the company’s stock worth $39,949,000 after purchasing an additional 256,042 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Zymeworks by 6.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 743,898 shares of the company’s stock worth $18,627,000 after acquiring an additional 43,896 shares during the period. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Latest Zymeworks News

Investors following ZYME have been watching these news items:

• Positive Sentiment: Citigroup raised its price target to $44 from $39 and maintained a Buy rating. Truist also forecast strong price appreciation, while TD Cowen lifted its target, adding to the positive analyst outlook. Truist Financial Forecasts Strong Price Appreciation for Zymeworks Zymeworks Stock Gets Price Target Boost from TD Cowen
• Positive Sentiment: Zymeworks recently reported better-than-expected earnings and reached a 52-week high, suggesting strong results had supported investor demand. Zymeworks Hits New 52-Week High After Better-Than-Expected Earnings
• Negative Sentiment: HC Wainwright cut estimates across several upcoming quarters and reduced its FY2026 EPS forecast to $1.19 from $1.51. Its FY2027 outlook shifted from expected earnings of $1.32 per share to a loss of $0.39 per share. These substantial revisions are a negative near-term signal, although the firm kept its Buy rating and $56 target. Zymeworks analyst and stock information

About Zymeworks

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.